FDA Approves Axi-Cel for Large B-cell LymphomaTargeted OncologyThe FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed or refractory large B-cell lymphoma, making the agent the second approved … Continue reading
FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer TreatmentPR Newswire (press release)The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric … Continue reading
Washington University School of Medicine in St. LouisNew gene-altering treatment offered for certain blood cancersWashington University School of Medicine in St. LouisAmanda Cashen, MD, examines patient Marie Miceli at Siteman Cancer Center at Barnes-… Continue reading
ForbesFDA Approves Another Amazing And Costly Cancer-Killing Gene TherapyForbesIn 2010, Josh Feldman was on his honeymoon — a globe-spanning trip that at one point involved swimming with humpback whales — when he noticed a "Garbanzo-sized" … Continue reading
|
FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin’s Lymphoma Patients
PR Newswire (press release) Yescarta is a Chimeric Antigen Receptor (CAR) T cell therapy, also known as CAR-T. Moffitt Cancer Center’s Frederick Locke, M.D., is the co-lead investigator of the pivotal ZUMA-1 clinical trial that tested the new therapy, which is manufactured by … FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin LymphomaOncLive |